Structurally distinct toxicity inhibitors bind at common loci on β-amyloid fibril

Ben Keshet1, Jeffrey J Gray, Theresa A Good

  • 1Department of Chemical and Biochemical Engineering, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, Maryland 21250, USA.

Insights

Researchers identified key binding sites on amyloid-beta (Aβ) fibrils, crucial for Alzheimer's disease toxicity. Understanding these sites on Aβ aggregates may lead to new therapeutic strategies.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Computational Biology

Background:

  • Accumulation of aggregated amyloid-beta (Aβ) is a hallmark of Alzheimer's disease (AD).
  • The precise mechanism of Aβ-induced neurotoxicity remains unclear.
  • Small molecules inhibiting Aβ fibril toxicity have been identified.

Purpose of the Study:

  • To investigate the binding sites of known Aβ toxicity inhibitors on Aβ fibrils.
  • To identify significant loci on Aβ aggregates for inhibitor action.
  • To gain insight into Aβ fibril surfaces critical for biological activity.

Main Methods:

  • Computational docking using the DOCK program to predict inhibitor binding sites on Aβ fibrils.
  • Experimental verification using lysine-specific chemical modifications.
  • Validation using Aβ fibrils mutated at specific residues (Asn27).

Main Results:

  • Two shared binding loci were identified: near Lys28 and at the C-termini (Asn27, Val39).
  • Structurally distinct inhibitors (Congo red, Myricetin) bound to the same sites.
  • Evidence suggests three additional inhibitors may bind to at least one of these sites.

Conclusions:

  • Common binding loci on Aβ fibrils were identified.
  • These loci are potential targets for understanding Aβ toxicity mechanisms.
  • Further research can explore the role of these binding sites in Aβ's biological activity.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...